Julie Johnson
Julie Johnson (D-TX) bought $1K-$15K of $MMM (3M Company Common Stock) on Jun 18, 2025, part of 3 transactions in this filing (2 buys, 1 sells).
HillSignal flagged 2 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
2 flagsThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
PFAS–Free Procurement Act of 2025
The PFAS-Free Procurement Act (HR3110) is an early-stage bill that would bar federal agencies from buying nonstick cookware and treated furniture/carpet containing PFOS or PFOA. The direct market impact is negligible — federal procurement of these specific items represents an insignificant fraction of revenue for $MMM and $DD. Broader PFAS regulation and litigation remain the dominant factors.
Intelligence Authorization Act for Fiscal Year 2026
The Intelligence Authorization Act for Fiscal Year 2026 (S. 2342) has been reported by the Senate Intelligence Committee and placed on the legislative calendar. The bill authorizes spending ceilings for FY2026 intelligence activities, providing structural revenue visibility for defense and intelligence contractors despite a 30-day selloff across defense primes. Actual funding requires a separate appropriations bill, but the authorization is a strong signal of Congressional intent supporting continued investment in intelligence technology, CPED modernization, and counter-UAS systems.
To amend title 23, United States Code, and the Infrastructure Investment and Jobs Act with respect to vehicle roadside crashes, work zone safety, and for other purposes.
HR2992 is an early-stage bill that expands data collection and public awareness for roadside and work zone safety, but authorizes no funding and mandates no new equipment or technology. It is in committee with no procurement or regulatory mandate, resulting in zero near-term market impact.
Fight Illicit Pill Presses Act
The Fight Illicit Pill Presses Act (S. 2870) is an early-stage, non-funding bill that expands DEA recordkeeping rules to makers of pill press equipment. With no procurement, subsidy, or prohibition, market impact is negligible. Illinois Tool Works ($ITW), the only publicly traded company plausibly in this manufacturing niche, faces no material financial effect.
Medical Research for Our Troops Act
HR3906 (Medical Research for Our Troops Act) would restore $1.181B in military medical research funding, but the bill has been stalled in the House Appropriations Committee since June 2025 with zero legislative movement. Real market data shows healthcare stocks declining 3-8% over 30 days due to broader sector headwinds, not this bill. No actionable trade signal exists.
Medicare for All Act
Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.
BUST FENTANYL Act
The BUST FENTANYL Act (S860) is a procedural bill that mandates new intelligence reports on fentanyl trafficking but authorizes zero new funding. The bill provides mild tailwinds for government contractors like $PLTR, $CACI, and $SAIC through existing contract vehicles, but near-term revenue impact is capped by the lack of appropriations. All three stocks have declined 4-6% in the past 30 days, reflecting broader sector weakness rather than legislative catalysts.
LAST ACRE Act of 2025
The LAST ACRE Act of 2025 (S.1617) is an early-stage authorization bill that creates a new USDA grant/loan program for broadband and wireless connectivity on active farmland. There is no funding amount specified, and the bill has only been referred to committee. Structural beneficiaries include tower REITs ($CCI, $AMT) and precision agriculture equipment makers ($DE), but actual market impact is zero until appropriations are passed. Real market data shows tower REITs have rallied 9% ($CCI) and 5.7% ($AMT) over 30 days on unrelated sector factors, while $DE is up 4.2% in the same period.
Other Filings by Julie Johnson
Free — no credit card
Get the next Johnson trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.